Japan now first to use oral Lonsurf (Tas-102)for mCRC that has seen standard treatment failures,
made by Taiho and soon to be tested worldwide
http://www.taiho.co.jp/english/news/20140324.html
and further down the road
www.newswise.com/articles/view/615426/?sc=dwhn
Comments
-
China is now studying fruquintinib (HMPL-013),
while the Netherlands is using a combo approach to inhibit both MEK and EGFR/ERBB2
and this may be of interest to someone
http://medicalxpress.com/print315209985.html
latest on CRC/aspririn
http://medicalxpress.com/print315487111.html
0 -
perspective
Thanks, Steve. "Yes" to the 1/4 aspirin. Taiho's new drug I had a "hmmmm, so so" reaction to their early results, side efffects for small gains. Note, I am still most impressed with Taiho's UFT, commercialized in the 1980's as the nicest 5FU chemo, when used skillfully.
The antibody drugs, to me are better lab creatures for all but the highest overexpressions. I am interested in their initial lab result for inhibition to guide treatment with natural inhibitors, but would rather have corresponding test markers guiding natural inhibitors use.
0
Discussion Boards
- All Discussion Boards
- 6 CSN Information
- 6 Welcome to CSN
- 120.7K Cancer specific
- 2.8K Anal Cancer
- 440 Bladder Cancer
- 304 Bone Cancers
- 1.6K Brain Cancer
- 28.4K Breast Cancer
- 388 Childhood Cancers
- 27.8K Colorectal Cancer
- 4.6K Esophageal Cancer
- 1.1K Gynecological Cancers (other than ovarian and uterine)
- 12.8K Head and Neck Cancer
- 6.3K Kidney Cancer
- 660 Leukemia
- 779 Liver Cancer
- 4.1K Lung Cancer
- 5K Lymphoma (Hodgkin and Non-Hodgkin)
- 232 Multiple Myeloma
- 7.1K Ovarian Cancer
- 47 Pancreatic Cancer
- 485 Peritoneal Cancer
- 5.2K Prostate Cancer
- 1.2K Rare and Other Cancers
- 531 Sarcoma
- 706 Skin Cancer
- 642 Stomach Cancer
- 190 Testicular Cancer
- 1.5K Thyroid Cancer
- 5.8K Uterine/Endometrial Cancer
- 6.3K Other Discussion Boards